ANAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AnaptysBio Inc (ANAB) is not a strong buy at this moment for a beginner investor with a long-term perspective. While the company has positive developments such as the spin-off of its biopharma operations and a stock repurchase plan, the technical indicators, options sentiment, and financial performance suggest a cautious approach. The stock has seen significant price appreciation over the past year, and the lack of clear buy signals from Intellectia Proprietary Trading Signals further supports a hold recommendation.
The MACD histogram is negative and contracting, RSI is neutral at 39.736, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 60.446, with key support at 55.57 and resistance at 65.323.
Spin-off of First Tracks Biotherapeutics set for April 20, 2026, with shareholders receiving shares in the new entity.
$100 million stock repurchase plan to enhance shareholder value.
Positive analyst sentiment with multiple price target upgrades, including Piper Sandler's target of $95 and UBS's target of $90.
Financial performance shows declining net income (-327.75% YoY) and EPS (-348.61% YoY) despite revenue growth.
No significant hedge fund or insider trading activity.
Technical indicators do not support a strong upward trend.
In Q4 2025, revenue increased by 151.08% YoY to $108.25 million, but net income dropped by -327.75% YoY to $49.61 million, and EPS fell by -348.61% YoY to 1.79. Gross margin remained steady at 100%.
Analysts are generally bullish, with multiple price target upgrades. Piper Sandler raised the target to $95, UBS to $90, and Stifel to $85, citing the potential of ANB033 and the spin-off of biopharma operations. However, Truist maintains a Hold rating due to pipeline concerns and legal overhang.
